Prognostic utility of the combination of pretreatment monocyte-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with NMIBC after transurethral resection.

Prognostic utility of the combination of pretreatment monocyte-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with NMIBC after transurethral resection. Biomark Med. 2019 Oct 17;: Authors: Wang Q, Huang T, Ji J, Wang H, Guo C, Sun X, Zheng K, Dong Z, Cao Y Abstract Aim: To investigate and validate predictive value of combination of pretreatment monocyte-to-lymphocyte ratio (MLR) and neutrophil-to-lymphocyte ratio (NLR) for disease free survival (DFS) and overall survival (OS) in nonmuscle invasive bladder cancer after transurethral resection. Materials &methods: Total 358 patients enrolled were assigned into three (MLR-NLR 0, 1 and 2) groups per the cut-off values of MLR and NLR. Results: Kaplan-Meier curves showed MLR, NLR and their combination were statistically associated with DFS (p
Source: Future Medicine: Biomarkers in Medicine - Category: Internal Medicine Tags: Biomark Med Source Type: research

Related Links:

As the Puget Sound region's biotech industry continues to grow, Seattle Genetics is leading the pack with its therapeutic for lymphoma on the market and two more late-stage products for bladder and breast cancer on the way. “Seattle Genetics has reached a transformational point in its history,” CEO Clay Siegall told the Business Journal. “Seattle Genetics will remain focused on making a meaningful difference in cancer patients’ lives through discovering, developing and commercializing transformative…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Source Type: news
Conclusions: The patients demonstrated a high level of safety, efficacy, and satisfaction with the ileal-vaginal extension for treating vaginal stump contracture after cervical cancer surgery combined with radiotherapy, suggesting that this method is valid for broad clinical application to improve the life quality of cervical cancer patients after surgery. PMID: 31739704 [PubMed - as supplied by publisher]
Source: Journal of Investigative Surgery - Category: Surgery Tags: J Invest Surg Source Type: research
ConclusionsThese consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time when further evidence is available to guide our approach.Patient summaryThis report summarises findings from an international, multistakeholder project organised by the EAU and ESMO. In this project, a steering committee identified areas of bladder cancer management where there is currently no good-quality evidence to guide treatment decisions. From this, they developed a series of proposed statements, 71 of which achieved consensus by a large group of experts in the field of...
Source: European Urology - Category: Urology & Nephrology Source Type: research
ConclusionsThere is a need for greater awareness and understanding of bladder cancer. Further research is warranted to promote early diagnosis and the timely treatment of bladder cancer.Graphical abstract
Source: Journal of Cancer Policy - Category: Cancer & Oncology Source Type: research
Authors: Brenner DR, Ruan Y, Shaw E, O'Sullivan D, Poirier AE, Heer E, Villeneuve PJ, Walter SD, Friedenreich CM, Smith L, De P Abstract BACKGROUND: Although cancer incidence over time is well documented in Canada, trends by birth cohort and age group are less well known. We analyzed age- and sex-standardized incidence trends in Canada for 16 major cancer sites and all cancers combined. METHODS: We obtained nationally representative population-based cancer incidence data in Canada between 1971 and 2015 from the National Cancer Incidence Reporting System (1969-1992) and the Canadian Cancer Registry (1992-2015). ...
Source: Canadian Medical Association Journal - Category: General Medicine Tags: CMAJ Source Type: research
UROLOGIC CLINICS OF NORTH AMERICA
Source: Urologic Clinics of North America - Category: Urology & Nephrology Authors: Source Type: research
Since its approval in the 1980s, Bacillus Calmette-Guerin (BCG) has been the key agent for management of high-risk nonmuscle invasive bladder cancer (NMIBC). However, response rates are about 50%, and those who do respond do not always have a durable response. Repeat intravesical instillation with BCG and chemotherapy can salvage a small proportion of the nonresponders or those who recur later during the disease course. Patients deemed unresponsive to BCG or chemotherapy are particularly hard to treat and often require radical cystectomy.
Source: Urologic Clinics of North America - Category: Urology & Nephrology Authors: Tags: Preface Source Type: research
Bacillus Calmette-Guerin (BCG)-refractory high-grade non –muscle-invasive bladder cancer remains a challenging problem. Radical cystectomy is standard of care, but carries significant morbidity. Therefore, there is a need for effective treatments. Previous salvage intravesical therapies have had disappointing results with long-term follow-up; however, a wide array of novel agents is currently under investigation. These include novel combinations of existing intravesical agents, novel modes of delivery such as hyperthermia, viral mediated therapies, and immunotherapy. We review the need for novel treatment with existi...
Source: Urologic Clinics of North America - Category: Urology & Nephrology Authors: Source Type: research
Due to significant risks of cancer recurrence and progression, and limited options after intravesical Bacillus Calmette Guerin (BCG) therapy, there is a critical unmet need to identify novel treatments for those patients with BCG-unresponsive bladder cancer. There is active investigation of immunotherapies which provide both biologic and clinical rationales for indoleamine-2,3- dioxygenase inhibitors in salvage therapy for non-muscle invasive bladder cancer.
Source: Urologic Clinics of North America - Category: Urology & Nephrology Authors: Source Type: research
This article provides a comprehensive review of the available data for immunotherapy being used as a salvage treatment in non –muscle-invasive bladder cancer. The literature demonstrates that the immune system has an important role in bladder cancer progression. Initial results from studies using checkpoint inhibitors, recombinant interferon-α2b protein, and oncolytic adenoviruses have shown promising responses with acc eptable toxicities. However, the majority of the current data arises from small trials with limited follow-up. There are currently several ongoing studies in this setting, which we await complet...
Source: Urologic Clinics of North America - Category: Urology & Nephrology Authors: Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Internal Medicine | Statistics